Mirati falls on updated response data for sitravatinib in NSCLC
Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data Monday from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus PD-1 inhibitor Opdivo nivolumab led to a confirmed overall response rate (ORR) of 16%, including nine complete (CR) or partial responses (PR). The confirmed ORR is about the same as the company reported in 23 evaluable patients in April. Mirati lost $6 (15%) to $34.01 on Monday.
The company said Monday the combination also led to two unconfirmed CRs/PRs in a pair of patients that remain on trial and are awaiting confirmation, and five unconfirmed CRs/PRs that will remain unconfirmed as the patients came off study. A preliminary estimate for median duration of response was more than nine months, and 18 patients showed tumor reductions of over 30%...